

Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN INC  
 Form 4  
 January 10, 2003

----- UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 FORM 4 WASHINGTON, D.C. 20549  
 -----

/ / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. SEE Instruction 1(b).  
 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP  
 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 Section 17(a) of the Public Utility Holding Company Act of 1935  
 Section 30(h) of the Investment Company Act of 1940  
 (Print or Type Responses)

1. Name and Address of Reporting Person*			2. Issuer Name AND Ticker or Trading Symbol	6. R
Skaletsky	Mark		ImmunoGen, Inc. (IMGN)	X
(Last)	(First)	(Middle)	3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	--
1365 Main Street				
	(Street)			
Waltham	MA	02451	4. Statement for Month/Day/Year	7.
(City)	(State)	(Zip)	January 9, 2003	
			5. If Amendment, Date of Original (Month/Day/Year)	<u>X</u>

TABLE I - NON-DERIVATIVE SECURITIES ACQUIRED, DI

1. Title of Security (Instr. 3)	2. Trans- action Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Trans- action Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Security Benefici Owned Fo ing Repo Transact (Instr. and 4)
			Code	V	Amount	(A) or (D) Price	
Common Stock	January 9, 2003		A	V	925	A \$3.24	7,491
Common Stock	January 9, 2003		A	V	967	A \$3.10	8,458

TABLE II - DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIAL  
 (e.g., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/ Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired, Disposed Of, Or Beneficially Owned (Instr. 3)	
				Code	V	(A)
7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Securities: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Edgar Filing: IMMUNOGEN INC - Form 4

Title	Amount or Number of Shares	Transaction(s) (Instr. 4)

Explanation of Responses:

/s/ MARK SKALETSKY	January 9, 2003
-----	-----
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, SEE Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, SEE Instruction 6 for procedure.